InnoCare Pharma Ltd (9969.HK) stock: key figures, P/E, revenue and dividend

Health Care · China · ISIN KYG4783B1032

Price
9.86 HKD
Market cap
17.38 bn HKD
P/E (2025)
23.40
P/S (2025)
7.32
Dividend yield
0.00 %
Net margin
27.05 %
Return on equity (ROE)
8.30 %
Return on assets (ROA)
5.94 %

InnoCare Pharma Ltd financials

Fiscal year20242025
Revenue1.01 bn CNY2.37 bn CNY
Gross profit1.01 bn CNY2.52 bn CNY
EBIT-607.00 m CNY573.00 m CNY
Net income-440.63 m CNY642.47 m CNY
Diluted EPS – continuing operations-0.32 CNY0.42 CNY

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About InnoCare Pharma Ltd

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.